Northwest Biotherapeutics Appoints Pat Sarma as Class II Director

TipRanksMar 23 04:42

Northwest Biotherapeutics Board Veteran Jasinowski Retires

TipRanksMar 15 04:44

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

Northwest Biotherapeutics (OTCQB: NWBO) announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system. In addition, the patent coverage of the Flaskworks system has been expanded: the foundational patent has been issued in the U.S. (and elsewhere) and an additional new patent application has been filed. The Company believes that this broad patent coverage will help it build a strong franchise.

PR NewswireFeb 6 22:30

Northwest Biotherapeutics Submits Marketing Authorization Application to UK MHRA for DCvax

Seeking AlphaDec 22, 2023 22:56

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma

Northwest Biotherapeutics (OTCQB: NWBO) announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax-L for glioblastoma brain cancer.

PR NewswireDec 21, 2023 22:30

Northwest Biotherapeutics(NWBO.US) Director Sells US$469.43K in Common Stocks

$Northwest Biotherapeutics(NWBO.US)$ Director MALIK NAVID sold 570K shares of Common Stocks on Nov 16, 17, 2023 at an average price of $0.824 for a total value of $469.43K.Source: Announcement What is

Futu NewsDec 2, 2023 10:09